Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation
A randomized, double-blind, placebo-controlled study
Volker Kühlkamp*,
Alexander Schirdewan ,
Karl Stangl ,
Michael Homberg ,
Matthias Ploch|| and
Otto A. Beck¶
* Eberhard-Karls-Universität, Tübingen, Germany
Franz-Volhard-Klinik, Humboldt-Universität, Berlin, Germany
Charité, Humboldt-Universität, Berlin, Germany
Krankenhaus Maria Hilf, Mönchengladbach, Germany
|| St. Antonius Hospital, Eschweiler, Germany
¶ Kreiskrankenhaus, Peine, Germany
View larger version (46K):
[in a new window]
|
Figure 1 Flow diagram of the study. AE: nonserious adverse event; SAE: serious adverse event.
|
|
View larger version (15K):
[in a new window]
|
Figure 2 Cumulative number of patients with relapse (atrial fibrillation/atrial flutter), subdivided by treatment group. The log-rank test of equality over treatment groups yielded a p value = 0.005; hence, the two treatment groups differ significantly with regard to the rate of relapse. The p value refers to the complete follow-up time (intention-to-treat approach).
|
|
View larger version (15K):
[in a new window]
|
Figure 3 Cumulative number of patients who had DC cardioversion with relapse (atrial fibrillation/atrial flutter), subdivided by treatment group. The log-rank test of equality over treatment groups yielded a p value = 0.002; hence, the two treatment groups differ significantly with regard to the rate of relapse. The p value refers to the complete follow-up time (intention-to-treat approach).
|
|
|
